

4basebio plc**(“4basebio” or the “Company”)**

À

Director’s Dealing

29 November 2024 – 4basebio PLC (AIM: 4BB) (“4basebio” or the “Company”), which develops and commercialises the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, announces that it was informed by Dr. Heikki Lanckriet, CEO of the Company, that he acquired ordinary shares in the Company through the market as follows:À

Name	Number of Shares Acquired	Price per Share (p)	Shareholding Following Acquisition	Shareholding as a Percentage of Issued Share Capital
Heikki Lanckriet	12,000	1,315p	1,115,288	7.27%

The issued share capital of the Company comprises 15,477,395 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

Enquiries**4basebio PLC**

+44 (0)1223 967 943

Dr. Heikki Lanckriet
Nominated Adviser

+44 (0)20 7213 0880

Cairn Financial Advisers LLP

Jo Turner / Sandy Jamieson / Ed Downes
Joint Corporate Broker

+44 (0)20 7653 4000

RBC Capital Markets

Rupert Walford / Kathryn Deegan
Joint Corporate Broker

+44 (0)20 7220 0500

Cavendish Capital Markets Limited

Geoff Nash / Nigel Birks

Notes to Editors**About 4basebio**

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1	Details of the person discharging managerial responsibilities/person closely associated	
a.	Name	Dr. Heikki Lanckriet
2	Reason for notification	
a.	Position/Status	CEO
b.	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a.	Name	4basebio plc
b.	LEI	31280050DY0541140220

D.	LEI	Z1380UEZDA9EAUUNCB3U				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares ISIN: GB00BMCLYF79				
b.	Nature of the transaction	Acquisition of ordinary shares				
			Price(s) per share (p)	Volume(s)		
			1,315p	12,000		
d.	Aggregated information • Volume • Price	• 12,000 • 1,315 pence per share				
e.	Date of the transaction	28/11/2024				
f.	Place of the transaction	London Stock Exchange, AIM				